Thermo Fisher Scientific, Inc. has acquired Cohesive Technologies, Inc., adding in-line sample preparation capabilities that couple with mass spectrometry technology to create end-to-end workflow solutions for drug and other organic molecule analyses. These new capabilities improve sample throughput and increase detection limits during LC/MS/MS analysis for customers in the pharmaceutical, clinical, environmental and food science industries. Based in MA, Cohesive Technologies manufactures advanced sample extraction and liquid chromatography products.

"Cohesive's sample preparation technologies will strengthen our ability to offer customers the advanced tools they need to accelerate research and discovery and to provide them with higher-quality analytical information," said Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific. "We look forward to integrating Cohesive into Thermo Fisher Scientific, and to making their sample preparation capabilities available to customers worldwide through our global sales channels."

Crucell has received its first orders for the CMO agreement with NJ-based Wyeth Biotech. The agreement for formulation and filing of a vaccine was finalized at the end of 2005 and will have the first business impact for Crucell in 2007. The vaccine will be supplied from Crucell's Swiss subsidiary.

Bob Tepper, M.D., R&D president, is leaving Millennium in the first quarter of 2007. Dr. Tepper was one of the founding executives in 1994 and was an integral part of its expansion from a drug discovery company to a fully-integrated biopharmaceutical company with nine novel molecules in development and market-leading product, Velcade for Injection for relapsed multiple myeloma and mantle cell lymphoma.

"Bob was one of a small group of people who had a vision for forming a new company that could make a difference in the way medicine is discovered to change the lives of patients," said Millennium president and chief executive officer Deborah Dunsire, M.D. "Today that vision is a reality and Millennium is indeed improving the lives of patients with multiple myeloma and mantle cell lymphoma, with a strong and diverse pipeline behind Velcade. I would like to thank Bob for his vision and relentless commitment to scientific excellence."

News from our sister sites